Globus Medical Q2 2026 Earnings: Revenue Beats $789.6 Million
Globus Medical (NYSE: GMED) reported Q2 2026 revenue of $789.6 million, up 5.9% year over year, and GAAP EPS of $1.10. Non-GAAP EPS was a record $1.34, beating consensus, and non-GAAP net income rose to $184.3 million. The company reaffirmed 2026 revenue guidance of $3.18–$3.22B and raised non-GAAP EPS guidance to $4.95–$5.05.
How this was made
The 30-second read
Why it matters
The key tradable items are the adjusted EPS beat, record non-GAAP net income, gross margin expansion, and the raised full-year non-GAAP EPS guidance while revenue guidance is reaffirmed. Segment commentary highlights stronger spine and trauma growth but a decline in Enabling Technologies revenue.
Market read
Investors get a fresh earnings datapoint plus a guidance raise, which can drive near-term repricing, tempered by segment weakness and a slightly negative extended-trading move.
What to watch
GAAP results are distorted by the prior-year Nevro bargain-purchase gain, so investors may focus on whether the enabling-tech decline is structural versus temporary.
Background
Globus Medical is a musculoskeletal/spine surgery and orthopedic technology company, and this article summarizes its Q2 2026 results and guidance changes.
Ticker impact
Globus Medical reported Q2 2026 revenue of $789.6M and record adjusted EPS of $1.34, beating consensus and raising full-year non-GAAP EPS guidance.
Bias modestly upward into the next few sessions, with volatility around guidance interpretation and segment mix.
The article discloses a concrete earnings beat, reaffirmed revenue guidance, and a raised EPS range, which are typically price-supportive. However, it also flags Enabling Technologies revenue decline and notes shares were slightly down in extended trading, implying investors are parsing segment/mix and margin sustainability.
Market effects
Musculoskeletal/spine medtech peers may see read-across on demand and margin trajectory, but the article provides no new peer-specific catalysts.
No explicit regional macro or regulatory drivers beyond company-reported U.S. and international growth.
Limited global relevance; this is primarily company-specific earnings and guidance.
Counterpoint
The adjusted EPS strength may be partly mix and margin-driven, while Enabling Technologies revenue fell sharply, which could pressure future growth quality.
Key entities
- public_companyGlobus Medical, Inc.
NYSE-listed musculoskeletal technology company reporting Q2 2026 earnings and guidance changes.
- executiveKeith Pfeil
President and Chief Executive quoted on momentum and segment growth.
- executiveKyle Kline
Chief Financial Officer quoted on margin expansion and record non-GAAP earnings.
